Stockwinners Market Radar for June 26, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:03 EDT Thomson Reuters to acquire Casetext for $650M - Thomson Reuters "announced it has signed a definitive agreement to acquire Casetext, a California-based provider of technology for legal professionals, for $650 million cash. The proposed transaction will complement Thomson Reuters existing AI roadmap and builds on its recent initiatives, including a commitment to invest more than $100 million annually on AI capabilities, the development of new generative AI experiences across its product suite, as well as a new plugin with Microsoft and Microsoft 365 Copilot for legal professionals. Founded in 2013, Casetext uses advanced AI and machine learning to build technology for legal professionals, creating solutions that help them work more efficiently and provide higher-quality representation to more clients. Casetext employs 104 employees, and its customers include more than 10,000 law firms and corporate legal departments. Casetext was granted early access to OpenAI's GPT-4 large language model, allowing it to develop solutions with the new technology and refine use cases for legal professionals. Its key products include CoCounsel, an AI legal assistant launched in 2023 and powered by GPT-4 that delivers document review, legal research memos, deposition preparation, and contract analysis in minutes."

20:08 EDT Cathie Wood's ARK Investment bought 274.4K shares of Nextdoor today

20:03 EDT Snowflake, Nvidia partner on Generative AI in Data Cloud - Snowflake (SNOW) and NVIDIA (NVDA) "announced at Snowflake Summit 2023 that they are partnering to provide businesses of all sizes with an accelerated path to create customized generative AI applications using their own proprietary data, all securely within the Snowflake Data Cloud. With the NVIDIA NeMo platform for developing large language models and NVIDIA GPU-accelerated computing, Snowflake will enable enterprises to use data in their Snowflake accounts to make custom LLMs for advanced generative AI services, including chatbots, search and summarization. The ability to customize LLMs without moving data enables proprietary information to remain fully secured and governed within the Snowflake platform."

18:08 EDT Starboard supports Abcam running full sale process - Starboard Value LP, a significant shareholder of Abcam, issued the following statement: "We believe there is significant value in Abcam and are supportive of the Company running a full sale process to maximize value for all shareholders. We are supportive of Dr. Milner's stated plan to temporarily suspend his solicitation to allow Abcam's Board of Directors to run a comprehensive review of strategic alternatives. If the Company is unable to complete a transaction, we agree that substantial change will be warranted."

17:58 EDT Trxade Health receives Nasdaq notice of noncompliance - According to a regulatory filing, on June 23, 2023, the Listing Qualifications department of The Nasdaq Stock Market LLC notified Trxade Health that the company was not in compliance with Nasdaq's listing rules as set forth in Listing Rule 5550(a)(4) given the company's failure to maintain a sufficient number of publicly held shares. Citing the company's Event Form submitted to Nasdaq on June 7, 2023, Nasdaq calculated the company's publicly held shares as approximately 310,057, on a post-split basis, effective as of June 22, 2023. To satisfy the requirement for continued listing on Nasdaq, the company must maintain a minimum of 500,000 publicly held shares. The Notice states that the company has until August 7, 2023 to submit a plan to regain compliance with Listing Rule 5550(a)(4). If Nasdaq does not accept the company's plan, the company will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel.

17:32 EDT AutoZone CEO Bill Rhodes to relinquish position, becoming Executive Chairman - AutoZone "announced Bill Rhodes' decision to relinquish his positions as President and CEO effective January 2024. He will become Executive Chairman of the Board. Philip B. Daniele, a 29-year AutoZoner and currently Executive Vice President Merchandising, Marketing and Supply Chain, has been selected to succeed Rhodes as CEO in January 2024 and he will also become a member of the Board of Directors."

17:26 EDT M.D.C. Holdings unit Richmond American closes on 78 homesites in Lake Hamilton - Richmond American Homes of Florida, a subsidiary of M.D.C. Holdings announces that it recently purchased and closed on 78 homesites in Lake Hamilton. The land is set to become part of Scenic Terrace, a new Polk County community featuring 744 homesites. This notable neighborhood will offer 12 single- and two-story floor plans from the builder's sought-after Seasons esigned to put homeownership within reach for a variety of buyers.

17:14 EDT General Dynamics awarded $257.6M Army contract modification - General Dynamics was awarded a $257.6M modification to a contract for M10 Booker low-rate initial production. Work has an estimated completion date of October 18, 2025. FY23 procurement of weapons and tracked combat vehicles, Army funds in the amount of $257.6M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:07 EDT Illumina sees charges of $25M-$35M in connection with job cuts - The Company estimates that it will incur aggregate charges of approximately $25M-$35M in connection with the reduction in force commenced on June 21 , and additional reductions this year. The Company expects that the majority of these charges will be incurred in the second quarter of 2023 and substantially all of these charges will have been incurred by the end of 2023. The Company estimates that substantially all of these charges will result in cash expenditures relating to severance payments, employee benefits and associated costs.

17:01 EDT Harbor Custom Development CFO Lance Brown to resign - Harbor Custom Development announced Lance Brown, Chief Financial Officer, will be resigning from the company, effective July 21, 2023. Brown's decision to resign does not relate to any disagreement with the company's management, the Board of Directors of the company, or the company's independent auditors regarding any matter pertaining to the company's operations, accounting practices, financial disclosures, internal controls, policies, or practices. The company has initiated a search for a new Chief Financial Officer to fill this position. "I am grateful for the opportunity to serve as the Chief Financial Officer of Harbor Custom Development and have immensely enjoyed the collaboration, trust, and shared commitment of all Harbor team members. I am confident in the future of Harbor and leave proud of my contribution to the strong foundation for sustained financial success," stated Lance Brown, Chief Financial Officer of Harbor Custom Development. The company expects to promote Yoshi Niino, Harbor's Director of Accounting since February 2022, to Chief Accounting Officer effective July 21, 2023. Upon assuming this role, Niino will execute the duties of the company's principal financial officer and principal accounting officer for Securities and Exchange Commission reporting purposes until the company hires a new CFO.

16:41 EDT Smart Powerr regains Nasdaq listing compliance - Smart Powerr announced that it received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC that, based on the Company's filings of Form 10-Q for the period ended March 31, 2023 on June 21, 2023, Nasdaq has determined that the Company complies with its Listing Rule 5250(c)(1). On June 21, 2023, the Company filed its quarterly reports on Form 10-Q for the periods ended March 31, 2023. Accordingly, Nasdaq has determined that the Company complies with the Listing Rule and closed the matter.

16:31 EDT S&W Seed appoints Mark Hermann CEO - S&W Seed Company announced the appointment of seed industry veteran Mark Herrmann as CEO effective July 1, following the planned retirement of current CEO, Mark Wong. Wong will continue to serve as a member of S&W's board. Herrmann has more than 35 years of experience in the seed industry, including as the CEO of AgReliant Genetics, the 3rd largest North American Seed Corn company and leader in Soybeans and other supporting crops, from January 2016 to July 2020.

16:29 EDT DiaMedica Therapeutics director and exec each buys $150K in common stock - In regulatory filing, DiaMedica Therapeutics disclosed that its director Richard Pilnik and Chief Business Officer David Wambeke each bought 38.36K shares of common stock on June 23rd in a total transaction size of $150K for each person.

16:17 EDT Modine Manufacturing director Moore sells 17,742 common shares - In a regulatory filing, Modine Manufacturing director Larry Oscar Moore disclosed the sale of 17,742 common shares of the company on June 22 at a price of $31.5792 per share.

16:16 EDT Mobileye CFO Anat Heller to step down due to personal reasons - Mobileye Global announced that CFO, Anat Heller, will be stepping down from her role for personal reasons, effective immediately. Due to a personal tragedy, Heller has decided to spend more time with her family. Following her resignation as Chief Financial Officer, Heller will continue at Mobileye and will serve as a strategic advisor to the Finance department and to senior management. Moran Shemesh Rojansky, Mobileye's current Vice President of Finance, will serve as the Company's acting Chief Financial Officer while a thorough search of internal and external candidates is conducted for a permanent replacement. Rojansky, 43, has served in various positions with Mobileye since 2016, most recently as Vice President of Finance and previously as Director of Finance and Corporate Controller. Prior to joining the Company, Rojansky served in financial reporting roles at Tnuva Ltd, including head of consolidation and reporting, for three years from 2013 to 2016, and in several roles prior to that in the accounting consulting services and advisory group at PwC, including as a senior manager.

16:11 EDT Erytech Pharma, Pherecydes announce merger and name change to Phaxiam - Erytech Pharma and Pherecydes announce merger and name change to Phaxiam Therapeutics, a clinical-stage biopharmaceutical company developing extended bacteriophage therapies to target antimicrobial resistance, or AMR. The combination will draw on the complementary expertise and resources of the two companies to accelerate the development of a global phage therapy portfolio, aimed at combating antimicrobial resistance, or AMR. The company is developing a pipeline of clinical stage extended phage therapies and expects significant value creation milestones in the next two years.

16:09 EDT Terns Pharmaceuticals shares new TERN-601 preclinical data at ADA - Terns Pharmaceuticals announced that new preclinical data from a transgenic mouse model evaluating TERN-601, the Company's novel oral GLP-1R agonist, were highlighted in a poster presentation at the American Diabetes Association's 83rd Annual Scientific Sessions, which took place from June 23-26, 2023 in San Diego. "We are excited by these new preclinical data shared at ADA, which demonstrate the ability of TERN-601 to significantly improve glucose tolerance, suppress food intake and slow gastric emptying in transgenic mice," said Sen Sundaram, chief executive officer at Terns. "These data are very encouraging and support our plans to initiate a Phase 1 first-in-human clinical trial in subjects with an elevated body mass index in the second half of this year, with top-line data expected in 2024."...In addition, Terns announces that management will participate in a Fireside Chat at the Piper Sandler Inaugural Obesity Investor Day and will host a webinar to review Terns' obesity franchise, including the TERN-601 program and additional development efforts underway in obesity.

16:07 EDT ReShape Lifesciences submits PMA supplement application to FDA for Lap-Band 2.0 - ReShape Lifesciences announced the submission of a Premarket Approval, or PMA, supplement application to the FDA for the company's next generation, enhanced Lap-Band 2.0, utilizing a band reservoir technology.

16:06 EDT United Insurance rejoins Russell 3000 and Russell 2000 Index - United Insurance Holdings announced that it has rejoined the broad-market Russell 3000(R) Index following the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opened today, June 26, 2023.

16:05 EDT Savara added to Russell 3000 Index - Savara "announced that it has been added to the U.S. broad-market Russell 3000 Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open on Monday, June 26, 2023."

16:02 EDT Edgewise Therapeutics announces positive 12-month topline results for EDG-5506 - Edgewise Therapeutics "announced positive 12-month topline results from the ongoing ARCH study, an open label, single-center study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics of EDG-5506 in adults with BMD. EDG-5506 is an orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies including BMD and Duchenne muscular dystrophy. The ARCH study is evaluating varying doses of EDG-5506 administered daily over 24 months in 12 adults with BMD. The Company is reporting data at the end of 12 months of treatment with EDG-5506. EDG-5506 was well-tolerated in all participants with no discontinuations or dose reductions due to adverse events. Consistent with prior observations, treatment with EDG-5506 led to significant decreases in key biomarkers of muscle damage. Importantly, CK and TNNI2 were reduced by an average of 37% and 79% from baseline, respectively, at the participants 12-month visit. After 12 months of EDG-5506 dosing, NSAA scores continued to trend in a positive direction. Nine of the twelve participants showed either a functional improvement or exhibited stable disease (n=3) on NSAA relative to their baselines. As seen in Figure 1, NSAA scores show a consistent positive trend that diverges from trajectories observed in the natural history studies reported by Bello et al. and van de Velde et al. (2021)2 in which the yearly decline was -1.2 NSAA points. Overall, one-year functional results were observed to have a +0.4-point improvement on the NSAA compared to the -1.2-point anticipated natural history decline in a population of BMD patients predicted to have a relentless course of disease progression."

16:00 EDT Adicet Bio reports 'positive' data from ongoing ADI-001 Phase 1 trial - Adicet Bio announced positive safety and efficacy data from the company's ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. "These data are exciting and beyond what one might expect to see given that patients enrolled in the study were heavily pre-treated," said Francesco Galimi, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Adicet Bio. "Autologous CD19 CAR T therapies were studied on CAR T naive patients with a median of 3 prior lines of therapy. In contrast, the ADI-001 Phase 1 trial enrolled patients with a median of 4 lines of prior therapy and, importantly, 50% had previously progressed on autologous CAR T therapy. Despite the advanced nature of the patients at baseline in the ADI-001 Phase 1 study, at our recommended Phase 2 dose (DL4) ADI-001 demonstrated an overall CR rate of 63%, a 6-month CR rate of 25%, and in patients that had progressed following autologous CD19 CAR T therapy, the CR rate of ADI-001 was 67% with a 6-month CR rate of 33%."

16:00 EDT Puyi Inc (ADR) trading resumes

15:45 EDT Puyi Inc (ADR) trading halted, volatility trading pause

14:38 EDT Wiley raises quarterly dividend to 35c per share - Wiley announced that its Board of Directors has declared a quarterly cash dividend of 35c per share on its Class A and Class B Common Stock, payable on July 20, 2023, to shareholders of record on July 6, 2023. The quarterly dividend is equivalent to an annual dividend of $1.40 per share, an increase from $1.39 per share in Fiscal 2023. It is Wiley's 30th consecutive annual increase.

13:32 EDT Tesla issues recall for 2023 Model 3, Model Y over battery disconnect issue - Tesla is recalling a limited number of 2023 Model 3 and Model Y vehicles over a potential defect in the pyrotechnic battery disconnect mechanism. Only 26 vehicles seemed to be potentially affected by the issue, according to a National Highway Traffic Safety Administration notice. "Tesla Service will replace the pyrotechnic battery disconnect, free of charge. Owner notification letters are expected to be mailed August 15, 2023," the notice reads. Reference Link

12:32 EDT American Rebel announces 1-for-25 reverse stock split - American Rebel will effect a reverse stock split of its outstanding shares of common stock, par value $0.001 per share, at a ratio of 1-for-25, to be effective as of 12:00 a.m. Eastern Time on June 27, 2023. Common Stock will begin trading on a reverse stock split-adjusted basis at the opening of The Nasdaq Capital Market on Tuesday, June 27, 2023. Following the reverse stock split, the Common Stock will continue to trade on Nasdaq under the symbol "AREB" with the new CUSIP number, 02919L307. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on Nasdaq. The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 16.9 million to approximately 677 thousand.

12:00 EDT Skillz falls -11.8% - Skillz is down -11.8%, or -$1.11 to $8.30.

12:00 EDT OneConnect falls -17.2% - OneConnect is down -17.2%, or -70c to $3.40.

12:00 EDT MoneyLion rises 19.0% - MoneyLion is up 19.0%, or $1.99 to $12.50.

11:49 EDT Bel Fuse announces sale of Jersey City building, relocation of corporate HQ - Bel Fuse announced that it has closed on the sale of its building in Jersey City, New Jersey for $5.9M. Bel's corporate office will transition to West Orange, New Jersey. Dan Bernstein, President and CEO, commented, "While we will certainly miss the city that we have called home for many decades, times are changing. The move to West Orange will improve the work-life balance for most of the 25 associates physically based out of our corporate office, reducing their commute. The timing makes sense due to the current market value of the property and our expectation of lower annual operating costs. This move supports our team and is in the best interest of our shareholders."

11:40 EDT Enfusion jumps 11%, halted after Reuters report on takeover interest

11:11 EDT PPG announces agreement with NRG Energy's Direct Energy - PPG (PPG) announced an agreement with NRG Energy (NRG) brand Direct Energy that will enable four PPG paints and coatings manufacturing facilities and 62 PPG PAINTS stores in Texas to reduce their carbon footprint. The initiative is estimated to reduce PPG's total greenhouse gas emissions by more than 9,400 metric tons annually, PPG said. "PPG has a strong history of focusing on energy efficiency and renewable energy sourcing, which has resulted in a 17% reduction in absolute GHG emissions since 2017 - but we know we must strive for more," said Diane Kappas, PPG vice president, global sustainability.

11:07 EDT Amazon to invest $7.8B in Ohio by 2030 for data center operations - Amazon.com announced an estimated investment of $7.8B by 2030 to expand its data center operations in Ohio, which it says "will bring hundreds of direct jobs and support thousands of additional jobs at local businesses through the construction, operations, and maintenance on-site at AWS facilities." Reference Link

10:29 EDT SHENGFENG DEVELOPMENT Ltd trading resumes

10:10 EDT ExcelFin Acquisition Corp trading resumes

10:00 EDT World Kinect falls -9.3% - World Kinect is down -9.3%, or -$2.10 to $20.53.

10:00 EDT Banco Macro rises 8.8% - Banco Macro is up 8.8%, or $2.23 to $27.54.

10:00 EDT ExcelFin Acquisition, Baird Medical enter business combination agreement - Baird Medical Investment Holdings and ExcelFin Acquisition entered into a definitive business combination agreement that would result in Baird Medical becoming a publicly traded company. Upon the closing of the proposed transaction between Betters and ExcelFin, the combined company will operate as Baird Medical Investment Holdings Limited and be listed on the Nasdaq under the new ticker symbol BDMD. The companies said, "Baird Medical is a leading microwave ablation medical device developer and provider in China. MWA has gained increasing recognition in China as a treatment for several tumor types, with benefits to patients, doctors, and public healthcare costs. According to Frost & Sullivan, Baird Medical is the largest MWA medical device provider for thyroid nodules and breast lump treatment in China." Baird Medical Investment Holdings Limited, a newly formed exempted company incorporated with limited liability in the Cayman Islands, will be the surviving public company following the consummation of the business combination.The combined company will have an estimated post-transaction enterprise value of $370M, assuming 50% redemptions by ExcelFin public shareholders. Proceeds from the transaction will be used to fund growth. The transaction includes a $15M minimum closing cash condition. To facilitate the transaction, Grand Fortune Capital, sponsor affiliate of ExcelFin, has agreed to purchase approximately $8.8M of Baird Medical's current debt from BOCI Investment Limited, one of Betters' current preferred shareholders. ExcelFin's and Baird Medical's respective boards of directors have unanimously approved the transaction, which is expected to close in the fourth quarter of 2023, subject to regulatory and shareholder approvals. Betters shareholders will roll 100% of their existing Betters equity holdings into ordinary shares of Baird Medical and are expected to own approximately 81% of Baird Medical on a non-fully diluted basis immediately following the closing of the proposed business combination, assuming 50% redemptions by ExcelFin's public stockholders.

09:55 EDT BioRestorative Therapies Inc trading resumes

09:50 EDT BioRestorative Therapies Inc trading halted, volatility trading pause

09:47 EDT World Kinect falls -5.7% - World Kinect is down -5.7%, or -$1.30 to $21.33.

09:47 EDT Carnival plc falls -9.4% - Carnival plc is down -9.4%, or -$1.34 to $12.92.

09:47 EDT Banco Macro rises 8.9% - Banco Macro is up 8.9%, or $2.24 to $27.55.

09:39 EDT ExcelFin Acquisition Corp trading halted, news pending

09:36 EDT FibroGen trading resumes

09:33 EDT Trxade Health Inc trading halted, volatility trading pause

09:29 EDT Dish COO Narayan Iyengar resigns - In a regulatory filing on Friday night, Dish disclosed that on June 19, Narayan Iyengar notified DISH Network Corporation that he was resigning as Executive Vice President and Chief Operating Officer effective June 23. "Iyengar will continue to provide transition support for a brief period of time," the filing stated.

09:17 EDT Amyris announce CEO transition, global reduction in force - Amyris announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announced cost reduction targets. As announced earlier this month, the Company has engaged the Business Recovery Services unit of PricewaterhouseCoopers to guide its transformation efforts. As part of this process, the Company aims to deliver Fit-to-Win cost actions of approximately $250M. This effort includes optimizing the costs of goods sold, reducing operating expenses and streamlining the business portfolio. "We are making tough choices including the decision to implement a reduction in force which we are executing today. We thank our departing employees for their efforts, dedication and contributions to Amyris," said Han Kieftenbeld, Interim Chief Executive Officer and Chief Financial Officer of Amyris. "I want to thank the Board for placing confidence in me to lead Amyris through this next phase. I will work closely with my leadership team and colleagues globally to set out a path towards profitable growth and sustained cash generation."

09:15 EDT Option Care Health confirms termination of merger agreement with Amedisys - Option Care Health (OPCH) announced that it has terminated its previously announced agreement to combine with Amedisys (AMED). As part of the mutual termination agreement, Option Care Health will receive a $106M termination fee. Consistent with Option Care Health's commitment to creating shareholder value, the Company will incorporate the termination fee into its established capital allocation strategy. "While we are disappointed in this outcome, Option Care Health has a long track record of delivering value for our shareholders," said John Rademacher, President and Chief Executive Officer of Option Care Health. "We take a disciplined approach to acquisitions and, as we evaluated our options, we applied this discipline to ensure we continue to create value for all of our key stakeholders."

09:14 EDT Taoping expands in Jiangxi province with AI-aided smart city cooperation - Taoping announced the Company is expanding into the Jiangxi Province and has entered into a new strategic cooperation agreement with Anyuan County to provide customized AI-aided Smart City solutions, which will leverage the Company's powerful new Cloud Nest AI system and intelligent Cloud platform to significantly help local digital transformation and development and ecological civilization construction. The strategic agreement is part of Anyuan County's Smart City transformation, with a dedicated economic and digital transformation. The parties will work together to implement a variety of Smart City programs and solutions, while also implementing tailored environmental enrichment solutions to protect the source water of the Dongjiang River, which supplies water to Hong Kong, and plays an important role to support the development of Guangdong-Hong Kong-Macao Greater Bay Area. Under the agreement, the two parties will carry out comprehensive cooperation in the fields of industrial investment, human intelligence, low-carbon environmental protection, Smart City renewal and rural ecological revitalization. The integrated solutions are 5G, AI-aided, Cloud-based and underpinned by Taoping's proprietary operating software. Taoping will provide its innovative Smart Rest Stations, lower cost, portable off-grid wastewater treatment solutions, and other related products and services, while Anyuan County provides market resources, policy support and fully assists the operation and development of the Company's projects in Anyuan County and surrounding counties and cities.

09:12 EDT Ansys appoints Weslock as VP of Human Resources - Ansys has named Kathleen Weslock, an industry veteran with decades of experience in human resources, labor relations, and mergers and acquisitions, as its vice president, VP, of human resources. Prior to joining Ansys, Weslock served as the Chief People and Culture Officer at Pep Boys during the American automotive aftermarket service chain's transformation to increase technology adoption in its legacy business.

09:11 EDT Richardson plans to expand eight elevators in Canada on CPKC Networl - Richardson International and Canadian Pacific Kansas City announced that Richardson plans to expand eight CPKC-served elevators in western Canada, allowing future trains to be moved from these sites under CPKC's 8,500-foot High Efficiency Product model. Work on the elevators in Manitoba, Saskatchewan and Alberta will start in the summer of 2023 and be complete by the end of 2024. "CPKC is thrilled to have these Richardson elevators added to the growing list of already qualified 8,500-foot HEP sites across western Canada," said John Brooks, CPKC's Executive Vice-President and Chief Marketing Officer. "Richardson's supply chain and CPKC's operation will benefit from added efficiency, capacity and fluidity with this investment. Richardson's ability to run longer trains will mean more grain shipped per train, tighter cycles and more Richardson trains moving across our expanded, single-line network throughout the season."

09:10 EDT Orex Minerals has secured surface access on Sandra Silver-Gold Project - Orex Minerals have secured surface access and core storage facilities for exploration on the Sandra Silver-Gold Project, located on lands of the Ejido "Escobar y Anexos" in Guanacevi, Durango, Mexico. The Sandra Project is held by Empresa Minera Sandra-Escobar S.A. de C.V., a 60:40 joint venture between Pan American Silver and Orex. A signing ceremony with the executives of the Ejido was conducted on 7 June 2023, with the presentation of a cheque as monetary compensation for the use of the land. The village of Escobar is located approximately 5 kilometres northwest of the Boleras Silver Deposit. Orex's President & CEO, Ben Whiting, P.Geo., said; "Positive engagement with the local community is an important part of our ongoing commitment to social responsibilities. Money provided this way will go directly to the needs of the local community."

09:09 EDT The Tile Shop opens new location in Colorado Springs - The Tile Shop now operates 143 retail showrooms in the United States. Located at 1730 East Woodman Rd, the approximately 10,000-square-foot retail showroom offers homeowners and trade professionals an exceptional design experience with over 6,000 natural stone, made-made and luxury vinyl tile products, setting and maintenance materials, accessories, and tools. In-store design experts will be available to guide customers through the entire project process from inspiration to installation and take the guesswork out of designing. With one of the largest selection of tile in America, starting at $1.35/sq. ft., there is a product for every project from do-it-yourself backsplashes to major remodels.

09:08 EDT Grom Social's Curiosity Ink Media, Dynamite announce four children titles - Curiosity Ink Media and its printed content partner, Dynamite Entertainment announced that the partnership will bring four new kids' titles, each of which celebrates everyone's favorite time of year, Christmas, that will be available through booksellers everywhere in time for Christmas, 2023. The titles represent three franchises from Curiosity's original IP offerings, as well as one book based on Cepia, LLC's hit toy and entertainment property, Cats vs Pickles. For Curiosity, the titles reflect the company's commitment to serving the consumer demands of the holiday season, alongside www.Santa.com, a digital holiday hub for grownups and kids

09:07 EDT Snowflake teams with Microsoft on large-scale generative AI, ML for data cloud - Snowflake (SNOW) announced an expanded partnership with Microsoft (MSFT), enabling new product integrations across AI, low code/no code application development, data governance, and more. The two companies will also implement new programs to enhance joint go-to-market strategies and improve field collaboration, bringing joint solutions directly to customers. As part of the partnership, Snowflake will increase its Azure spend commit, with both companies jointly supporting go-to-market efforts. "Snowflake's partnership with Microsoft is evolving and focused on improving our field collaboration to help our customers enter the next wave of generative AI," said Chris Degnan, Chief Revenue Officer, Snowflake. "Our integrations with Microsoft's generative AI and LLM services will enable joint customers to leverage the latest AI models and frameworks, enhancing the productivity of developers."..Snowflake will expand its strategic initiatives with Microsoft to empower data scientists and developers with industry-leading AI solutions, build new integrations between the Data Cloud and Azure ML, and leverage integrations with Azure OpenAI and Microsoft Cognitive Services. With the Azure ML integration, joint customers will be able to accelerate the entire development to production workflow for machine learning with access to the latest frameworks, integrated CI/CD, and more. Additionally, to leverage the latest in AI innovation to build intelligent data products, both companies are committed to working toward enabling Snowflake customers to easily and securely leverage Azure OpenAI and Microsoft Cognitive Services with Snowflake data.

09:05 EDT Smart for Life enters distribution agreement with Two Hands Corporation - Smart for Life announced an agreement with Two Hands Corporation. The announcement was made jointly by Nadav Elituv, President of Two Hands Corporation and Darren Minton, CEO of Smart for Life. Smart for Life's distribution agreement with Two Hands Corporation is expected to result in initial shipments of products into Canada beginning in Q3 2023.

09:03 EDT Security National Financial declares 5% stock dividend - Security National Financial announces that on June 23, 2023, its Board of Directors has authorized a 5% stock dividend for stockholders of record on July 7, 2023. The stock dividend will be issued on July 14, 2023.

09:00 EDT Moolec Science announces data on Piggy Sooy platform - Moolec Science announced an achievement in its Meat Replacements Program for the Soybean platform, as its new "Piggy Sooy" produced a significantly high amount of pork protein. The animal protein reached a high expression level up to 26.6% of total soluble protein in soy seeds, 4x higher than initially projected by the Company. The result can be directly observed due to the pink color of Moolec's soybeans, the same color as the pig. After this achievement, the Company's soybean platform was renamed "Piggy Sooy". The breakthrough accomplishment has led Moolec to file a new patent utilizing a novel approach aiming to provide the Company with a frictionless regulatory pathway going forward. This scientific milestone consolidates the Molecular Farming path as one of the most valuable alternative technologies to produce animal proteins, given that plants can function as animal protein factories in a more efficient manner than initially expected. This enhanced efficiency of plants has the potential to improve the economics of the Company's business model. Moolec Science is producing several meat proteins in plants as functional ingredients to improve the taste, appearance, texture, and nutrition of meat alternatives. Due to its enhanced functionality and final application, the Company also highlighted that these food ingredients could also be potentially commercialized within the ~$600 billion traditional processing meat industry.

08:57 EDT Glimpse Group's Brightline awarded contract with U.S. Air Force - Brightline Interactive is part of a team that was awarded a Direct-to-Phase II contract through AFWERX - a technology directorate of the U.S. Air Force Research Laboratory and the innovation arm of the Department of the Air Force. BLI will work alongside prime contractor BCI Solutions and fellow subcontractor, Purdue University, with a total initial award value in the low seven figures.

08:55 EDT ARC Document receives improved terms in credit agreement amendment - ARC Document Solutions has entered into an amendment to its credit agreement that increases the amount of restricted payments the company can make and exclude from its fixed charge coverage ratio. Such restricted payments include the use of cash for issuing dividends and repurchasing company stock. During a time when credit terms are generally becoming more restrictive, ARC's management attributed the favorable terms of its credit agreement amendment to its strong financial performance over the past several years and the continuing strength of its balance sheet. As part of its commitment to return shareholder value, ARC also disclosed the purchase of 506,403 shares of its own stock via open market transactions from April through the first three weeks of June. The number of shares represents 1.2% of ARC's outstanding shares, and the average share price paid by the company during the period was $2.95. ARC's trading window for purchasing its own shares during the second quarter closed on Thursday, June 22, 2023. At its most recent meeting in April, ARC's Board of Directors authorized the expansion of the company's previous $15 million share repurchase program to $20 million thru March 2026. Including the purchase of 506,403 shares of ARC stock announced today, the company has repurchased approximately 13% of its outstanding shares since 2019. Management expects to have approximately $10 million available for continuing share repurchases as of June 30, 2023.

08:54 EDT Linde, Smart Eye sign deal for AIS driver monitoring system - Smart Eye will deliver its complete hardware and software Driver Monitoring System to Linde in the Nordic and Baltic countries.

08:52 EDT Mace Security partners with Meyer Distributing - Mace Security entered into a distribution agreement with Meyer Distributing. The agreement provides for the distribution of pepper spray and other personal defense products through Meyer's distribution network

08:50 EDT Conduent highlights solutions for public organizations at CTSE conference - Conduent will host a roundtable discussion at the Council of State and Territorial Epidemiologists Annual Conference. Presenters will demonstrate how the company helped one large municipality consolidate several databases into one advanced system for capturing and analyzing childhood lead data. CTSE 2023 kicked off in Salt Lake City, Utah on June 25 and runs through June 29. Today's roundtable session begins at 12:45 pm local time in the Brighton Room. Conduent will also showcase its Maven Disease Surveillance & Outbreak Management System and Healthy Communities Institute solutions.

08:47 EDT P10 joins Russell Indexes - P10 has joined the broad-market Russell 2000 Index. Annual Russell index reconstitution captures the 4000 largest US stocks as of April 28, ranking them by total market capitalization, including the Russell 3000 and Russell Microcap Indexes. Being included in the Russell 3000 means P10 will also be included in the Russell 2000.

08:45 EDT Wolfspeed confirms $1.25B financing deal with Apollo Credit Funds - Wolfspeed (WOLF) "announced a $1.25B secured note financing from an investment group led by Apollo (APO), with an accordion feature for up to an additional $750 million. The financing supports the company's previously announced U.S. expansion efforts and is a significant step toward achieving the company's $6.5 billion global capacity expansion plan. Execution of Wolfspeed's U.S. growth plan will accelerate adoption of silicon carbide across a wide array of end markets and support meaningful job creation in US semiconductor manufacturing. The 9.875% notes will mature in 2030 and are optionally prepayable by the company based on the terms of the indenture governing the notes. The investment was led by funds managed by Apollo's ~$450 billion Credit business." Shares of Wolfspeed are up 4.6% in pre-market trading at $51.74.

08:43 EDT HeartCore Enterprises signs deal with Honda Trading for CONTROLIO solution - HeartCore Enterprises has executed a deal with Honda Trading Corporation for its task mining software solution, CONTROLIO, a web-based cloud system for employee monitoring and productivity enhancement.

08:41 EDT Artelo Biosciences presents data from preclinical studies of ART12.11 - Artelo Biosciences announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, presented important new data from multiple preclinical studies regarding ART12.11, Artelo's patented cannabidiol cocrystal, on Sunday, June 25th, at the 33rd International Cannabinoid Research Society Symposium in Toronto, Ontario, Canada. "We are delighted to have the opportunity to disclose new, and potentially groundbreaking research findings from our ongoing, preclinical development program with ART12.11, which demonstrate improved bioavailability and efficacy in nonclinical models of stress-induced anxiety versus CBD," said Gregory D. Gorgas, President and CEO of Artelo. "Given the strong potential safety profile and latest efficacy data, we believe ART12.11 has an opportunity to play a major role within the global anxiety and depression market, which Fortune Market Insights estimates to be in excess of $11 billion. These latest results provide us further confidence of the potential of ART12.11 to improve outcomes, especially for people suffering from anxiety disorders and the complications of PTSD. Looking ahead, our proprietary CBD cocrystal will be a key element of our overarching strategy to introduce innovative, patented and differentiated therapeutic solutions into clinical practice for patients facing significant unmet needs."

08:40 EDT St. James Gold signs letter of consent to enable New Found Gold seismic survey - St. James Gold has signed a letter of consent to let New Found Gold conduct a single line 2D seismic survey over its Grub Line Property in Newfoundland. The results of any survey relating to any portion of the Company's property will be made available to the Company. The planned survey is expected to occur in July with data becoming available in the fourth quarter of 2023. The planned survey would be a new survey and is in addition to the 3D seismic survey announced by NFGC on March 7, 2023 occurring on their adjacent Queensway Project

08:38 EDT NewtekOne joins Russell 3000, Russell 2000 Indexes - NewtekOne has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index following the conclusion of the Russell indexes annual reconstitution for 2023, effective upon today's US market open.

08:36 EDT Ryman Hospitality appoints Patrick Moore as CEO of OEG division - Ryman Hospitality Properties announced that its former Board of Directors member Patrick Moore has been appointed Chief Executive Officer of its Opry Entertainment Group division. Moore's responsibilities include oversight of OEG's growth plan, day-to-day operations, and business development activities.Moore brings decades of experience leading brands through periods of transformative growth, including his most recent position as Executive Vice President, North America Retail for Carter's, Inc.

08:35 EDT Forge Global added to U.S. Small-Cap Russell 2000 Index - Forge Global Holdings announced that it has been added as a member of the U.S. Small-Cap Russell 2000 Index as part of the 2023 Russell U.S. Index's annual reconstitution. Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index. "Forge's inclusion in the Russell 2000 Index is particularly timely as we continue to drive value to institutional investors, including through our first index - the Forge Private Market Index," said Kelly Rodriques, CEO of Forge. "We believe inclusion in this iconic index strengthens our position as an industry leader. We look forward to increasing our visibility within the institutional investor community - through our index, our data and as a proxy to private market performance, as we continue to deliver on our long-term vision to create an accessible, transparent and liquid private market." Forge is a leading provider of marketplace infrastructure, data services and technology solutions for private market participants. By combining a leading trading platform and operating expertise, Forge enables private company shareholders to trade private company shares with accredited investors. Forge helps provide additional transparency, access and solutions that companies as well as institutional and accredited investors can use to confidently navigate and efficiently transact in the private markets.

08:34 EDT DSS announces record, distribution date for Impact Biomedical spin-off dividend - DSS has filed for the distribution of a special stock dividend to DSS Inc. shareholders of record on June 30 for distribution on July 14, 2023. DSS shareholders of record as of 4:00 p.m. ET on June 30, 2023 will receive four shares of Impact Biomedical, Inc. for every one share of DSS.

08:33 EDT Panbela Therapeutics announces presentation on results for CPP-1X - Panbela Therapeutics announces a poster presentation highlighting the results for CPP-1X in recent onset type 1 diabetes at the Endocrine Society meeting, which was held June 15-18, 2023. The work reflects the Company's ongoing collaboration with Indiana University School of Medicine. The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes research and advocacy organization. The preclinical data were generated by Raghavendra Mirmira's laboratory at the University of Chicago. Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies. The poster investigates the mechanism of polyamines and polyamine inhibition by CPP-1X on beta cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models. Human islet cells were either treated with vehicle or CPP-1X and RNA sequencing and proteomics were performed. Results showed that CPP-1X treatment of stressed human islets cells resulted in altered pathways related to endoplasmic reticulum-related protein processing, antigen presentation, and reactive oxygen species. In vivo studies in mice with beta cell-specific deletion of ODC showed improved glucose tolerance, increased beta cell mass, and reduced incidence of diabetes following streptozotocin treatment. In the Phase 1 dose range finding study of in patients with recent onset T1D, CPP-1X was well tolerated and a dose dependent inhibition of ODC was observed. An exploratory secondary analysis showed that at the two highest dose levels, treatment with CPP-1X stabilized C-peptide areas under the curve compared to placebo. When assessing immune cell populations, there were no differences between the placebo and CPP-1X patients. Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve beta cell function and/or survival in recent onset T1D.

08:32 EDT Citius Pharmaceuticals to be added to Russell 3000, Russell 2000 Indexes - Citius Pharmaceuticals announced that it is set to be added to the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the annual reconstitution of Russell US Indexes, effective at the opening of the U.S. equity markets on June 26, 2023. "We are pleased to be included, once again, in the Russell U.S. Equity Indexes and welcome the enhanced visibility this brings to our diversified late-stage pipeline," stated Leonard Mazur, Chairman and CEO of Citius.

08:31 EDT Ocean Biomedical issued patent for bispecific cancer immunotherapy treatment - Ocean Biomedical announced that a new, broad U.S. patent for bispecific antibodies targeting chitinase 3-like-1 and programmed cell death protein 1, a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a "master regulator" of tumor growth in multiple visceral cancers, has been issued to one of its Scientific Co-founders, Dr. Jack A. Elias, MD. Ocean Biomedical's bispecific antibody is a immunotherapy approach that demonstrates promising synergy by combining Ocean's proprietary anti-CHi3L1 antibody with existing immune checkpoint inhibitors that target PD-1 in a bispecific-antibody format. As seen in the image below, these bispecific antibodies have been shown to synergistically kill tumor cells at levels dramatically exceeding the effectiveness of either the anti-CHi3L1 antibody or the anti-PD-1 antibody alone-in multiple cancer types and multiple animal models. Ocean Biomedical's breakthrough comes at a critical time for the evolving immuno-oncology sector, which is working to realize the promise of immune checkpoint inhibition. Current challenges include the limited number of cancer patients demonstrating initial responses and the significant number of responders relapsing following classic immune checkpoint blockade. Ocean Biomedical's new approach combines Ocean's anti-CHi3L1 antibody with classic immune checkpoint blockade, and the initial magnitude and duration of response from Ocean's bispecific immunotherapy treatment in multiple animal models of visceral cancer was synergistically enhanced compared to immune checkpoint blockade alone. The new bispecific patent has been granted for prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer. The newest claims dovetail with and fortify recently issued patents with claims coverage focused on composition of matter of monoclonal antibodies targeting and inhibiting CHi3L1.

08:29 EDT Agile Therapeutics announces availability of Twirla to MMCAP Infuse Members - Agile Therapeutics announced that Twirla will become available to MMCAP Infuse Members effective July 1, 2023. The Company expects this increased availability to positively impact growth of demand and factory sales in the non-retail channel, which grew 20% and 15% respectively from the fourth quarter 2022 to first quarter 2023. MMCAP Infuse has over 26,000 member facilities in all 50 states, including state agencies, counties, cities, and school districts,. This partnership with MMCAP Infuse reinforces Agile's commitment to making Twirla available to as many patients as possible.

08:27 EDT Cidara Therapeutics added to Russell Microcap Index - Cidara Therapeutics joined the broad market Russell Microcap Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The newly reconstituted Index will become effective after the U.S. equity market opens on Monday, June 26, 2023.

08:26 EDT Sutro Biopharma, Blackstone enter royalty financing collaboration - Sutro Biopharma (STRO) and Blackstone (BX) announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront, with up to an additional $250 million in future milestone payments triggered at various return thresholds, in exchange for Sutro's 4% royalty, or revenue interest, in the potential future sales of Vaxcyte's products, including VAX-24 and other products that Vaxcyte develops under its license with Sutro. Vaxcyte's lead candidate, VAX-24, is a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine with enhanced serotype coverage and immunogenicity. Vaxcyte's PCV franchise is enabled by Sutro's XpressCF cell-free protein synthesis technology.

08:25 EDT Benitec Biopharma receives FDA clearance of IND for BB-301 - Benitec Biopharma announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for BB-301, its silence and replace gene therapy for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia. Subjects from Benitec's ongoing NH study will be eligible for rollover onto the Phase 1b/2a clinical study of BB-301 for the treatment of OPMD-related Dysphagia after 6 months of baseline data collection. Following a 1-day dosing procedure for BB-301, each study subject will be evaluated for the same radiographic and clinical outcome measures as were evaluated during the NH study, including quantitative radiographic swallowing studies to facilitate objective assessments of swallowing safety, swallowing efficiency, and functional performance of the pharyngeal muscles underlying the OPMD-related Dysphagia. Currently, there are 13 subjects enrolled into the NH study, with each subject having the potential to rollover onto the Phase 1b/2a clinical dosing study for BB-301. Interim safety and efficacy data is expected to become available from the BB-301 Phase 1b/2a study approximately every 90 days following the dosing of each subject.

08:23 EDT InspireMD completes enrollment in C-Guardians IDE clinical trial - InspireMD completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption clinical trial, designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system. The C-Guardians clinical trial is evaluating the safety and efficacy of the CGuard Carotid Stent System for the treatment of carotid artery stenosis. The study, which commenced enrollment in July 2021, enrolled 315 patients across 25 trial sites in the U.S. and Europe. The trial includes both symptomatic and asymptomatic patients undergoing carotid artery stenting. The primary endpoint includes the composite of the following: incidence of the following major adverse events: death, all stroke, and myocardial infarction through 30-days post-index procedure, based on the Clinical Events Committee adjudication or ipsilateral stroke from 31-365-day follow-up, based on CEC adjudication. The performance goal will be considered to have been met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is less than11.6% and the p-value is less than0.025.The company anticipates results from the study in H2 2024.

08:18 EDT Femasys announces FDA approvalof IDE for FemBloc clinical trial - Femasys announced the approval of an Investigational Device Exemption from the United States Food and Drug Administration to evaluate the safety and efficacy of FemBloc, a first-of-its-kind, non-surgical, non-implant, in-office solution for permanent birth control in a pivotal clinical trial.

08:16 EDT Eyenovia added to Russell 2000, Russell 3000 Indexes - Eyenovia announced that the company was added to the small cap Russell 2000 and broad market Russell 3000 Indexes effective today.

08:15 EDT Twist Bioscience validates GLP-1R antagonist antibody as CHI treatment - Twist Bioscience announced publication of preclinical data supporting the potential use of the highly potent and optimized GLP-1R antagonist antibody, TB-222-023, as a treatment for congenital hyperinsulinism . This pediatric genetic disorder has estimates of prevalence ranging from 1 in 25,000 to 1 in 50,000 live births in the U.S., which could translate into a steady-state treatable population of up to 2,500 cases in the U.S. It is caused by excessive pancreatic beta cell insulin secretion, resulting in hypoglycemia that can cause brain damage or death without treatment. "Patients with congenital hyperinsulinism have few treatment options. The promising results from our studies described in the Diabetes paper demonstrate that targeting GLP-1R with an antibody antagonist, such as TB-222-023, could be an effective strategy for the treatment of this very serious condition," said De Leon-Crutchlow..."GLP-1R is very high profile within the industry and targeting this receptor with potent therapeutic candidates has potential in several medical conditions in addition to CHI, such as post-bariatric hypoglycemia," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "This paper describes the power of Twist's highly specific and potent antibody libraries as well as our ability to then optimize and improve on resulting candidates. The fact that TB-222-023 showed potency higher than a Phase 3 ready clinical candidate peptide is very promising. TB-222-023 has the potential to be a first-in-class antibody, a modality with advantages over peptides. We are now looking for partners to help take TB-222-023 and related antibodies forward in development."

08:14 EDT WiMi Hologram announces development of phase target classification technology - Hologram Cloud announced the development of a single-pixel digital holography-based compressive phase target classification technology. It is a digital holography-based target identification and classification technology. The technology utilizes the principle of single-pixel digital holography imaging to capture the interferogram of a target by synthesizing the wave field in the object plane. And the interferogram is mapped to the CCD camera through the spatial light modulator for digital processing to extract the target phase information and then complete the target identification and classification process.

08:13 EDT Orchestra BioMed to join Russell 3000 Index - Orchestra BioMed is set to join the broad-market Russell 3000 Index, the small-cap Russell 2000 Index, and the Russell Microcap index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens today, June 26, 2023, according to a preliminary list of additions posted May 19, 2023.

08:12 EDT Enlivex Therapeutics expects cash to fund operations into 2025 - As of March 31, 2023, Enlivex had cash and cash equivalents, short term bank deposits and long term interest-bearing bank deposits of $43.2 million. The Company believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements potentially into 2025.

08:11 EDT Corbus Pharmaceuticals set to join Russell Microcap Index - Corbus Pharmaceuticals announced that the Company is set to join the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today, as part of the 2023 Russell indexes reconstitution.

08:11 EDT Enveric announces Phase 1-ready formulation for EB-373, enhanced manufacturing - Enveric Biosciences announced the development of an improved formulation of EB-373 designed to enhance the drug product's scalability, stability, and delivery for ongoing preclinical studies and planned clinical development. EB-373, Enveric's lead product candidate, is a new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder. The optimized, Phase 1-ready formulation of EB-373 utilizes a novel salt form that is expected to enable more efficient and scalable manufacturing of drug material. Enveric and its CDMO partner, which specializes in development of psilocin-based active pharmaceutical ingredients for large-scale manufacturing, will collaborate on non-GMP manufacturing of sub-kilogram amounts of the EB-373 salt form in the near term, followed by GMP manufacturing in the coming months. The optimized formulation and manufacturing will immediately support the completion of preclinical work and will enable Enveric to fill requirements with the Australian regulatory authorities towards the initiation of clinical trials. "The work by our team of chemists and our CDMO partner has enabled Enveric to take a key step towards the clinic with the development of an optimized formulation and manufacturing process for EB-373," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "We now possess a formulation of EB-373 that is ideally suited for the large-scale production that is needed for later-stage clinical trials and eventual commercialization, while maintaining the drug properties that make EB-373 a potentially groundbreaking treatment of anxiety disorder, including the potential for more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs."

08:10 EDT Ashford Securities announces $500M in capital raised since 2021 - Ashford Securities announces that it has reached a milestone of $500M, including $42.1M from institutions, in capital raised in less than two years of serving investors via the independent broker-dealer and RIA distribution channels. Ashford Securities previously served as the managing broker-dealer for Braemar Hotels & Resorts and currently serves as the managing broker-dealer for Ashford Hospitality Trust and a growth-oriented private offering that is targeting investments in all types of commercial real estate in the state of Texas. C. Jay Steigerwald III, President and Head of Distribution of Ashford Securities commented, "Our goal is to provide highly differentiated investment products to financial intermediaries. I would like to take this opportunity to thank all of our distribution partners for our tremendous success. Without their confidence, trust, and support this would not have been possible. We are very excited about what the future holds for Ashford Securities."

08:09 EDT Chijet Motor announces first board meeting after business combination - Chijet Motor Company announces that the first board of directors meeting was held on June 16, 2023. Led by Mu Hongwei, Chairman of the Board of Directors of Chijet, the board discussed the Company's business with the members of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. The meeting confirmed the newly constituted board, consisting of: Mr. Mu Hongwei, Chairman; Mr. Zhang Jiannong; Mr. Wu Lichun; Mr. John Chiang; Non-Employee Director; Mr. Simon Pang Non-Employee Director; Ms. Ying Liu Non-Employee Director; Mr. Wen Li Non-Employee Director.

08:08 EDT Sprinklr to join small-cap Russell 2000 - Sprinklr announced that the company will join the small-cap Russell 2000 and broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26.

08:08 EDT Avita Medical rejoins Russell 3000 Index - AVITA Medical announced that it has rejoined the broad-market Russell 3000 Index following the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

08:07 EDT Cheniere and ENN sign long-term LNG sale and purchase agreement - Cheniere Energy (LNG) announced that Cheniere's subsidiary, Cheniere Marketing has entered into a long-term liquefied natural gas sale and purchase agreement with ENN, a wholly-owned subsidiary of ENN Natural Gas. Under the SPA, ENN has agreed to purchase approximately 1.8m tons per annum of LNG from Cheniere Marketing on a free-on-board basis for a purchase price indexed to the Henry Hub price, plus a fixed liquefaction fee. Deliveries will commence in mid-2026, ramping to 0.9 mtpa in 2027. Delivery of the remaining 0.9 mtpa, which is subject to, among other things, a positive Final Investment Decision with respect to the first train of the Sabine Pass Liquefaction Expansion Project will commence upon the start of commercial operations of Train Seven. The term of the SPA extends until the 20th anniversary of the start of commercial operations of Train Seven. "We are pleased to build upon our existing long-term relationship with ENN, a leader in China's rapidly growing natural gas industry, with this 20-plus year agreement signed today," said Jack Fusco, Cheniere's President and Chief Executive Officer. "This SPA further supports China's structural shift to natural gas as a growing primary energy source, powering its economy while enabling improved environmental performance with flexible, reliable and cleaner LNG. This SPA accelerates Cheniere's commercial momentum on the SPL Expansion Project, demonstrating the market's need for additional LNG capacity, and the value of Cheniere's unique capability to tailor long-term solutions for customers worldwide." The SPL Expansion Project is being developed to include up to three natural gas liquefaction trains with an expected total production capacity of approximately 20 mtpa of LNG. In May 2023, certain subsidiaries of Cheniere Energy Partners American (CQP) entered the pre-filing review process with respect to the SPL Expansion Project with the Federal Energy Regulatory Commission under the National Environmental Policy Act.

08:06 EDT Assure Holdings to purchase assets from Innovation Neuromonitoring for $1.2M - Assure Holdings announced that it has signed a Letter of Intent to purchase certain assets of Innovation Neuromonitoring for approximately $1.2 million in a cash and equity transaction. Established in 2016, Innovation is a leading IONM company primarily serving the Greater Dallas, Texas and Charleston, South Carolina regions. In 2022, Innovation performed more than 4,000 IONM procedures and approximately 51% of these procedures were with commercial insurance payors. The company currently employs 18 full-time staff, including 13 technologists supporting more than 50 surgeons at over 40 facilities. The purchase price to be paid is $800,000 in cash and $400,000 in Assure common stock, subject to escrow and other requirements. Under the LOI, Assure will acquire Innovation's contracts, employees, business relationships, equipment and other assets. Approximately $500,000 of the $800,000 cash will be paid over 24 monthly installments, with adjustments based on the number of surgeries and the commercial payor mix. The proposed Acquisition will take the form of either an asset or equity purchase by Assure at its choice at closing. The transaction is expected to close in early July subject to, among other things, customary closing conditions, satisfactory due diligence and the negotiation and execution of a definitive asset purchase agreement.

08:05 EDT Acorda Therapeutics regains compliance with Nasdaq - Acorda Therapeutics announced that it has received notification from Nasdaq informing the company that as of June 20 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450. Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.

08:05 EDT Clene announces publication of Phase 2 CNM-Au8 clinical data - Clene announced that The Lancet's journal eClinicalMedicine has published combined detailed analyses of the Phase 2 RESCUE-ALS study and its open-label extension trial. "Results from RESCUE-ALS study were important because they provided the first insights about the clinical benefits of CNM-Au8 in ALS patients and the duration of treatment required to detect them," said Professor Steve Vucic, PhD, DSc, Northcott Chair of Neurology, The University of Sydney, and a co-investigator of the RESCUE-ALS study. "The treatment effect demonstrated a clear survival signal associated with CNM-Au8 treatment and evidence for delayed clinical worsening morbidity events such as tracheostomy and initiation of feeding tube during the double-blind placebo-controlled period. Additional functional benefits such as decreased worsening of ALSFRS-R scores are emerging later through the long-term open-label extension."

08:04 EDT Leidos adds Carahsoft to Alliance Partner Network - Leidos announced the addition of Carahsoft Technology Corp as a Corporate Alliance Partner to the Leidos Alliance Partner Network, LAPN. LAPN drives innovation through a vast network of the world's leading technology companies and leverages significant expertise to provide solutions that deliver customer mission success. The Corporate Alliance Partner tier represents the highest level of partnership in Leidos and is reserved for partners who have demonstrated excellence in providing innovative solutions, joint investment, business capture support, supply chain resilience and business execution. "Carahsoft embodies our shared values and commitment to our customers on the forefront of innovation," said Leidos Chief Procurement Officer Bob Gemmill. "This collaboration will enable Leidos to leverage Carahsoft's extensive distribution network, public sector expertise and influence to better serve government customers with leading-edge solutions."

08:03 EDT Trinity Capital appoints DaCruz as Managing Director, Life Sciences - Trinity Capital (TRIN) announced the continued expansion of its life sciences team with the appointment of Igor DaCruz as Managing Director, Life Sciences, and the opening of a new office in the San Diego area. DaCruz brings to Trinity over 12 years of experience in the life sciences industry, having established himself as a trusted investment professional with previous experience at Runway Growth Capital and Silicon Valley Bank (SIVB).

08:01 EDT BlackBerry software now embedded in over 235M vehicles - BlackBerry has determined BlackBerry QNX software is now embedded in over 235 million vehicles worldwide; a year-over-year increase of 20 million. "In ten years, BlackBerry QNX has expanded from being in over 16 million vehicles to over 235 million today. Undoubtedly, we are the market leader for secure and safety-certified automotive software," said John Chen, Executive Chairman & CEO, BlackBerry. "As vehicles become increasingly software-defined our value proposition becomes even more critical to their development and the smart cities they are central to the advancement of. BlackBerry is pleased to be the long-standing and trusted partner of the automotive industry, and to be key to the emergence of a trusted smart world."

08:01 EDT Infosys signs collaboration pact with Danske Bank - Infosys "announced that it has signed a strategic collaboration with Danske Bank, a leading Nordic Bank, to accelerate the bank's digital transformation initiatives with speed and scale. This collaboration will help Danske Bank achieve its strategic priorities towards better customer experiences, operational excellence, and a modernised technology landscape, powered by next-gen solutions. As part of this collaboration, Infosys will also acquire Danske Bank's IT center in India, where over 1,400 professionals are employed. With its global expertise and industry-solutions, Infosys will accelerate the bank's digital agenda by significantly enhancing their IT operations and capabilities, powered by Infosys Topaz, an AI-first set of services, solutions and platforms, experience design, and services that support operations."

07:56 EDT NFI Group provides timing update on comprehensive refinancing plan - NFI Grou provided an update on the expected timing to complete its previously announced comprehensive refinancing plan. NFI expects to concurrently complete all elements of its Refinancing Plan prior to the release of its second quarter financial results on Wednesday, August 2, 2023. To support this expected timing, NFI has received an extension of the date for the completion of the required amendments and the financial covenant waivers under the Company's existing North American senior secured credit facility to July 31, 2023 and August 4, 2023, respectively. NFI has also received confirmation of the extension of the maturity date and financial covenant waivers under its senior secured UK credit facility to August 4, 2023. These extensions are subject to customary conditions. To date, under the Refinancing Plan NFI has: received confirmation of credit approval from its banking partners for proposed amendments to the Secured Facilities with maturity dates extending to April 30, 2026; received confirmation of intention to extend the maturity of Manitoba Development Corporation's and Export Development Canada's senior unsecured debt facilities to April 30, 2026, with both facilities extensions subject to final approvals and documentation; secured approximately $225 million of equity commitments through a combination of a private placement transaction and a bought deal public offering of subscription receipts to be exchanged for common shares of NFI on completion of the Refinancing Plan; and significantly advanced a planned $175 million second lien debt financing, with discussions with potential investors ongoing. NFI continues to expect this financing to have a coupon in the range of 12% to 15% and an anticipated maturity of 3.5 to 5 years. In connection with the Private Placement, the Company has received approval under the Competition Act and the waiting period under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired. The Company has also received the conditional approval of the Toronto Stock Exchange for the listing of the Shares issuable in the Private Placement. Listing is subject to NFI fulfilling all of the requirements of the TSX on or before September 22, 2023. As all of the financing transactions described above are mutually conditional, the Company expects to close all elements of the Refinancing Plan at the same time prior to August 2, 2023.

07:52 EDT ParkerVision appoints Lewis Titterton to board of directors - ParkerVision has appointed Mr. Lewis Titterton, Jr. as a Class II director to fill a vacancy on the company's board of directors. Mr. Titterton previously served on the ParkerVision board from September 2018 until April 2019 when he resigned due to family medical issues.

07:50 EDT Point Biopharma, AdvanCell partner to develop radioligands - POINT Biopharma and AdvanCell announced a collaboration on the development of a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network to specifically support the clinical development and commercialization of 212Pb-labeled radioligands by each company. 212Pb is differentiated as both an alpha and beta-emitting isotope with a simple decay chain that has demonstrated promising clinical results in compassionate use and phase 1 settings. 212Pb is produced via a generator using thorium or radium sources. 228Th is available in significant quantities and has a half-life that supports 212Pb generators with ~1 year shelf-lives stationed at a selected number of regional locations globally. The short half-life of 212Pb as the benefit of delivering greater than99% of the tumor cell-killing radiation in only 72 hours, which reduces the time that the ligand needs to be retained in the tumor, a common limitation for targeted radioligand therapies. The short half-life may also promote the earlier maintenance of functional immune cells infiltrating the tumor relative to longer-lived isotopes. In contrast, only ~20% of the decays from 225Ac occur in 72 hours, so prolonged tumor retention is required to achieve the same payload delivery

07:46 EDT Freeline doses first patient in Phase 1/2 GALILEO-1 trial of FLT201 - Freeline Therapeutics announced that the first patient has been dosed in the Phase 1/2 GALILEO-1 clinical trial evaluating FLT201, its adeno-associated virus gene therapy candidate, in Gaucher disease type 1. Gaucher disease is a debilitating genetic disorder in which a deficiency of the GCase enzyme leads to a buildup of fatty substances in the organs, causing symptoms including enlarged spleen and liver, low blood counts, bone pain and reduced lung function. GALILEO-1 is a first-in-human, international, multicenter Phase 1/2 dose-escalation study. The trial will assess safety, tolerability and efficacy of a single intravenous dose of FLT201 in up to four cohorts of escalating doses, with the aim of identifying a dose for further development in a Phase 3 clinical trial. Visit clinicaltrials.gov to learn more about GALILEO-1. Freeline expects to report initial data, with a focus on safety and enzyme activity, from the first cohort of GALILEO-1 in the third quarter of this year.

07:44 EDT Avicanna, Medipharm Labs expand strategic manufacturing agreement - Avicanna (AVCNF) announced the extension of its existing strategic manufacturing agreement with Medipharm Labs (MEDIF) for the commercialization of Avicanna's proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems technology capsules for the Canadian and international markets. Under the expanded Strategic Manufacturing Agreement, Avicanna intends to commercialize its proprietary SEDDS technology capsules, under the RHO Phyto brand, across domestic nation-wide medical channels including the Avicanna's MyMedi.ca online cannabis care platform and MediPharm's Canna farms platform. Additionally, MediPharm intends to commercialize the capsules across adult use wellness channels under its MediPharm Labs brand. MediPharm intends to manufacture these proprietary capsules in accordance with GMP standards to fulfill domestic and international pharmaceutical standards. The expanded Strategic Manufacturing Agreement provides that each of Avicanna and MediPharm may take steps towards offering these products internationally through existing internal infrastructure and externally with parties under contract.

07:42 EDT Dragonfly Energy joins Russell 2000 Index - Dragonfly Energy announced it has joined the Russell 2000 Index.

07:40 EDT Ayr Wellness reaches contingent agreement to defer promissory note payments - AYR Wellness is providing an update with respect to its previously announced initiative regarding capital structure alternatives and extending upcoming debt maturities. The Company has now reached contingent agreements to defer principal or amortization payments for 2 years on an aggregate principal amount of approximately US$69 million of debt obligations, including contingent agreements with holders of approximately US$60.5 million aggregate principal amount of vendor take-back promissory notes representing 67.4% of the outstanding principal amount of all vendor notes maturing before 2027. The Company has also reached contingent agreements to defer the maturities of US$4.5 million of other promissory notes, as well as a $4 million amortization payment due in December 2023. More specifically, the US$69 million aggregate amount includes amendments with respect to: Vendor notes issued by CSAC Acquisition PA II Corp. to former minority interest holders of Pennsylvania based PA Natural Medicine on March 22, 2022, and earn-out promissory notes issued by CSAC Acquisition PA II Corp. to former minority interest holders of PA Naturals on March 1, 2022, with an aggregate outstanding principal amount of approximately US$34.4 million, which extend the maturity thereof by 2 years; Vendor notes issued by CSAC Acquisition NJ Corp. on September 15, 2021 to former interest holders of New Jersey based GSD NJ, with an aggregate outstanding principal amount of approximately US$13.1 million, which extend the maturity thereof by 2 years; Vendor notes issued by CSAC Acquisition PA Corp. on December 23, 2020 to former interest holders of Pennsylvania based CannTech, with an aggregate outstanding principal amount of approximately US$11.1 million, which extend the maturity thereof by 2 years; Promissory notes assumed by certain subsidiaries of the Company in connection with the GSD and CannTech acquisitions in favor of former minority interest holders, with an aggregate outstanding principal amount of approximately US$4.5 million, which extend the maturity thereof to October 31, 2023 and will further extend the maturity thereof by 2 years upon fulfillment of certain conditions; A vendor note originally issued by CSAC Acquisition IL Corp. on May 25, 2022 to a former interest holder of Illinois based Herbal Remedies Dispensaries, LLC, which defer a US$4 million amortization payment by 2 years; and Vendor notes originally issued by CSAC Acquisition Inc. on November 18, 2020 to former interest holders of Pennsylvania based DocHouse, LLC, with an aggregate outstanding principal amount of approximately US$1.9 million, which extend the maturity thereof by 2 years. Included in the US$69 million total amount of deferred principal and amortization payments are the previously announced amendments to US$27.7 million principal amount of vendor notes entered into upon completion of the Company's acquisition of GSD and CannTech as well as promissory notes assumed by CSAC Acquisition PA Corp. in connection with the CannTech acquisition. As previously announced, the Company also amended the earn-out terms related to the Company's acquisitions of GSD and Sira Naturals, which resulted in an extension of the payment terms for approximately US$27.9 million of cash and amortization payments. As a result of the collective amendments to the vendor notes, promissory notes, and earn-out payments, the Company has now successfully extended the payment terms of a cumulative of US$96.9 million of obligations. In connection with the above vendor note and promissory note amendments, the Company has agreed to interest rate adjustments that will result in a blended interest rate increase of approximately 0.5% across the US$69 million aggregate principal amount. The Company also agreed to pay amendment fees with respect to certain of the above amendments aggregating US$0.4 million that will be capitalized to the principal amount of certain vendor notes.

07:38 EDT SL Green Realty sells 49.9% interest in 245 Park Avenue - SL Green Realty has sold a 49.9% interest in 245 Park Avenue to a U.S. affiliate of Mori Trust Co., Ltd. at a gross asset valuation of $2B. SL Green acquired the 1.8 million-square-foot, headquarters-quality office property on the coveted Park Avenue corridor between 46th and 47th Streets in September 2022 with the intent to reposition the asset with a partner. The company has retained Kohn Pedersen Fox Associates to assist in a redesign of the building that is focused on a new Park Avenue podium facade, new windows, improvements to both the Park Avenue and Lexington Avenue lobbies, the Park Avenue plaza, retail storefronts, numerous infrastructure upgrades, and an expansion of SL Green's premier amenity program. The sale of a joint venture interest in 245 Park Avenue is the largest component of the company's financial plan for 2023, following the $500M refinancing of 919 Third Avenue in April.

07:37 EDT Camping World to acquire Arkansas-based multi-location RV dealer CrainRV - Camping World Holdings announced that it is set to acquire multi-location RV dealer Crain RV in Arkansas. Crain operates locations in Benton, Springdale, and Little Rock, predominantly selling Jayco, Winnebago, Tiffin, Coachmen, and Forest River products. The acquisition is anticipated to close in the fourth quarter of 2023. Camping World intends to convert these locations into Manufacturer Exclusive dealerships upon completion of property and facility improvements. Marcus Lemonis, Chairman and CEO of Camping World commented, "The Crain RV acquisition is an example of widening our acquisition funnel by identifying targets that allow for conversion to Manufacturer Exclusive locations. Our goal is to achieve 50% percent growth in our store count over the next five years."

07:36 EDT Aehr Test Systems added to Russell 3000 Index - Aehr Test Systems announced that it has been added to the Russell 3000 Index as part of the 2023 Russell index annual reconstitution, effective after the US stock market opens.

07:35 EDT Vertex Pharmaceuticals and Lonza to build facility for T1D cell therapies - Vertex Pharmaceuticals announced a strategic collaboration to support the manufacture of Vertex's portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials. Vertex's first clinical program, VX-880, has already demonstrated clinical proof-of-concept. In new data released last week, all six patients treated with VX-880 engrafted islet cells, produced endogenous insulin and had improved glycemic control, while reducing or eliminating insulin use. Patients with greater than 90 days of follow-up had elimination of severe hypoglycemic events in the evaluation period. Vertex's second approach, VX-264, utilizes the same fully differentiated insulin-producing islet cells as in VX-880 and is being studied in a Phase 1/2 clinical trial. In VX-264, the cells are encapsulated in a proprietary device designed to shield the cells from the body's immune system, thereby eliminating the need for immunosuppression. In a third approach, Vertex's hypoimmune program, the same cells are edited to cloak them from the immune system; this program continues to progress in preclinical development. Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire. Operated by Lonza, the facility will span more than 130,000 square feet and is anticipated to create up to 300 new jobs at peak capacity. Construction is scheduled to begin later this year.

07:35 EDT Super Group added to Russell 2000 Index - Super Group announced that it has been added to the Russell 2000 Index.

07:34 EDT Cambium Networks drives increased momentum in hospitality, MDU markets - Cambium Networks has registered growth in the hospitality and multi-dwelling unit, MDU, markets on the strength of its network connectivity solutions - that in turn has fueled record enterprise revenue growth for the company. Coming out of the pandemic, the hospitality industry is transforming the way it interacts with travelers. Touch-less technology and the exponential growth of personal streaming have led to changes in connectivity requirements. Secure, digital connectivity is now mission critical, across entire properties, for both guests and operations. "Our growing presence in the hospitality and MDU industries reflect the strength of our product lines, offering these properties the network connectivity technologies they need to serve their customers," said Cambium Networks president and CEO Atul Bhatnagar. "With Cambium Networks, the diverse connectivity needs of large properties can now be managed from the cloud using a single pane of glass. As a result, property owners no longer must choose between cost and exceptional digital experiences."

07:32 EDT Spirit AeroSystems continues talks with IAM - Spirit AeroSystems announced that it will continue talks with the International Association of Machinists and Aerospace Workers, IAM, on Monday, June 26, following constructive and positive meetings through the weekend. "We have been working hard and making good progress," said Tom Gentile, President and CEO of Spirit AeroSystems. "We will continue discussions this week and remain committed to a timely resolution on a fair and competitive contract that addresses the priorities of our employees and other stakeholders." Spirit AeroSystems is a subsidiary of Spirit AeroSystems Holdings.

07:31 EDT Nauticus Robotics announces inclusion in Russell Microcap Index - Nauticus Robotics announced its addition to the Russell Microcap Index at the conclusion of the 2023 annual reconstitution, effective after the US market opens today on June 26, 2023.

07:30 EDT Flyht Aerospace, Flair Airlines enter agreement for hardware, services - Flair Airlines and FLYHT Aerospace Solutions announced an agreement for the purchase of FLYHT's hardware and services. FLYHT will enable Flair to closely monitor its fuel and greenhouse gas emissions for every phase of flight operations, including when an aircraft is at the gate, taxiing, at idle, during takeoff and at cruise. The data allows Flair to find opportunities to increase fuel efficiency and reduce the carbon footprint on its fleet of Boeing 737 MAX aircraft.The contract is valued at approximately US$3.6 million, provided that all products and services are delivered over the 5-year term of the agreement. F

07:27 EDT FibroGen to implement cost reduction effort to extend runway into 2026 - FibroGen plans to implement a significant cost reduction effort in the U.S. with the intent to extend our cash runway into 2026.

07:25 EDT FibroGen says Phase 3 ZEPHYRUS-1 study did not meet primary endpoint - FibroGen announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis. The study compared treatment with pamrevlumab to placebo and did not meet the primary endpoint of change from baseline in forced vital capacity at week 48. The mean decline in FVC from baseline to week 48 was 260 ml in the pamrevlumab arm compared to 330 ml in the placebo arm. The secondary endpoint of time to disease progression was also not met. In the safety analysis, pamrevlumab was generally safe and well tolerated and the majority of treatment emergent adverse events were mild or moderate. Treatment-emergent serious adverse events were observed in 28.2% of patients in the pamrevlumab group and 34.3% of patients in the placebo group. Based on the results of ZEPHYRUS-1, ZEPHYRUS-2, the second Phase 3 clinical trial, will be discontinued. FibroGen plans to communicate the results of the ZEPHYRUS-1 study at an upcoming medical forum. "We are deeply disappointed that these results do not support pamrevlumab as a new treatment for IPF," said Mark D. Eisner, MD, MPH, Chief Medical Officer, FibroGen. "FibroGen would like to thank the patients and clinical trial investigators for their dedication to participating in this study." FibroGen anticipates reporting topline data from Phase 3 studies with pamrevlumab for the treatment of ambulatory DMD patients in 3Q 2023, locally advanced pancreatic cancer in 1H 2024, and metastatic pancreatic cancer.

07:23 EDT Marker Therapeutics reports MT-401 non-clinical data in AML cells - Marker Therapeutics reports non-clinical data on its lead multi-tumor-associated antigen-specific T cell product candidate, MT-401, which showed increased anti-tumor activity against an acute myeloid leukemia cell line after treatment with hypomethylating agents. Marker further announces that the Company has been awarded a $2M grant from the National Institutes of Health Small Business Innovation Research program to support the development of MT-401 for the treatment of patients with AML after hematopoietic stem cell transplant. The multiTAA-specific T cell technology from Marker uses a novel non-genetically modified T cell therapy approach that recognizes multiple antigens expressed on tumor cells, thereby designed to minimize tumor escape. MT-401 was designed to specifically target four different antigens, which are upregulated in AML but have limited expression on normal cells. In March 2023, Marker reported clinical updates from the Company sponsored ARTEMIS clinical trial highlighting the potential benefit of MT-401 in patients with AML who have measurable residual disease after HSCT. Given the promising responses in patients who are MRD+, Marker has been investigating clinical opportunities to further improve AML patient outcomes. One such opportunity is to combine multiTAA-specific T cell therapy with agents that make cancer cells more visible to cancer killing cells. This opportunity has practical merit because HMAs that do this, such as 5'-Azacytidine and Decitabine, are commonly used as therapies for AML. It also has scientific merit because these agents inhibit DNA methylation, a process which regulates gene expression. By reducing DNA methylation, HMAs can restore physiological gene expression patterns, including the upregulation of tumor suppressor genes, and the inhibition of oncogenes. HMAs have also been found to upregulate the expression of tumor antigens, including MT-401-specific tumor antigens, previously silenced by DNA methylation. Due to this mechanism of action, Laura S. Angelo, Ph.D., and her team at Marker investigated in a set of in vitro experiments, the capacity of MT-401 to inhibit or kill THP-1 cells, an aggressive treatment-resistant AML cell line, after the cells were exposed to HMA. In this in vitro model of treatment resistant AML, tumor cells exposed to HMA for 72 hours upregulated tumor-associated antigen targets of MT-401, including Survivin. The THP-1 cell line was bioluminescent modified to allow real-time long-term assessment of cancer cell growth. THP-1 cells continued to grow both in the absence and presence of DMSO, the vehicle used to dissolve 5'-Azacytidine. The growth of THP-1 cells was reduced in the presence of 5'-Azacytidine. The growth of THP-1 cells was also reduced in the presence of MT-401. THP-1 cell growth, however, was significantly decreased when MT-401 was added after exposure to 5'-Azacytidine compared to MT-401 or 5'-Azacytidine administration alone, suggesting a synergistic effect between the two agents. These in vitro data demonstrate that administration of MT-401 following HMA infusion enhanced AML cell killing and could offer a new therapeutic option for AML patients post-HSCT. Based on this non-clinical data, Marker received a $2 million grant from the NIH. The awarded SBIR grant will support a nationwide multi-center Phase 2b clinical trial in AML patients following HSCT to evaluate the effect of MT-401 administered after pre-treatment with HMAs. This proposed Phase 2b study includes evaluation of efficacy and safety of MT-401, as well as immune monitoring of patient samples. AML is considered an orphan indication and in 2020, MT-401 was granted orphan designation by the U.S. Food and Drug Administration for treatment of patients with acute myeloid leukemia.

07:19 EDT Mobilicom to showcase drone, robotics solutions at Modern Day Marine 2023 - Mobilicom announced it will showcase its end-to-end solutions to procurement specialists from the U.S. Marine Corps at Modern Day Marine 2023 in Washington D.C. on June 27-29, 2023. Showcased solutions will include Mobilicom's military-grade cybersecure solutions for avionic, maritime, and ground unmanned drone and robotics platforms operating in the most stringent environments. Live demonstrations will be conducted on a robotic vehicle to prove the power of combining and simultaneously operating end-to-end solutions that are designed to work together from one leading provider-Mobilicom. Mobilicom's ICE Cybersecurity suite shields from cyberattacks its hardware and software products including the SkyHopper Combo used for communications and its mobile ground control stations for ruggedized remote control of drones and autonomous vehicles.

07:17 EDT Trevena announces OLINVYK data from ARTEMIS study - Trevena announced new topline OLINVYK data from the ARTEMIS study. The ARTEMIS study was an electronic medical records based assessment focused on clinical and health resource utilization outcomes at Cleveland Clinic and Wake Forest Baptist Health. The study reviewed OLINVYK-treated patients in the ~200 patient VOLITION study with comparable surgical patients treated with other IV opioids, at the same institutions and during the study period. New topline data includes data from OLINVYK-treated patients and matched patients at Cleveland Clinic, as well as measures of cost per admission at both Wake Forest Baptist Health and Cleveland Clinic for OLINVYK-treated and matched patients. Initial ARTEMIS data from Wake Forest Baptist Health was previously announced based on OLINVYK-treated patients compared to matched patients at that site. Overall Data from Cleveland Clinic and Wake Forest Baptist Health. OLINVYK-treated patients had a $8,756 reduction in average cost per admission and 1.4-day reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids. Based on the data we have to date, there was not a statistically significant difference in the average duration of time in the post-anesthesia care unit between OLINVYK-treated and matched patients. Cleveland Clinic Results. OLINVYK-treated patients had a $7,102 reduction in average cost per admission and a 0.9-day reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids at Cleveland Clinic. Wake Forest Baptist Health Results. OLINVYK-treated patients had a $10,339 reduction in average cost per admission compared to matched patients treated with other IV opioids at Wake Forest Baptist Health. The Company previously announced that OLINVYK-treated patients at this site had a 1.6 day reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids.

07:15 EDT Assertio Holdings joins Russell 3000 Index - Assertio Holdings has joined the broad-market Russell 3000 Index as part of the 2023 reconstitution, completed at the close of market on June 23.

07:14 EDT ALX Oncology receives orphan drug designation from EC for evorpacept - ALX Oncology Holdings has received orphan drug designation from the European Commission for the treatment of patients with gastric cancer. This ODD indication includes both gastric cancer and gastroesophageal junction adenocarcinoma. The U.S. Food and Drug Administration also granted ODD to evorpacept for the treatment of patients with GC as previously announced in January 2022.

07:13 EDT Avalo Therapeutics says AVTX-002 did not meet primary endpoint in Phase 2 trial - Avalo Therapeutics announced topline results from the Phase 2 randomized, double-blind, placebo-controlled trial evaluating AVTX-002 in patients with poorly controlled non-eosinophilic asthma. The trial did not meet its primary endpoint, measured by the reduction in asthma-related events. AVTX-002 demonstrated a favorable safety and tolerability profile. AVTX-002 significantly reduced LIGHT levels for the study duration indicating target engagement. Additionally, an exploratory analysis revealed a positive trend in reduction of asthma related events in patients treated with AVTX-002 as compared to placebo within a substantial sub-population of patients with elevated baseline LIGHT levels. Dr. Michael Wechsler, Professor of Medicine, Director of Asthma Program at National Jewish Health and the PEAK Trial's Principal Investigator, said: "Although this study did not reach its primary endpoint in this patient population, we have identified a positive trend in a sub-population of patients with high baseline LIGHT levels. This is exciting because it gives us a potential novel biomarker for treatment in patients with severe non-eosinophilic asthma, for whom new therapies are urgently needed. Further analyses to better characterize the patients that responded to this novel treatment are ongoing and should inform future studies in asthma where regulation of LIGHT could be beneficial for these patients."

07:11 EDT Tonix to acquire Zembrace SymTouch, Tosymra from Upsher-Smith - Tonix Pharmaceuticals and its wholly-owned subsidiary Tonix Medicines announced that they have entered into an agreement to acquire two currently-marketed products from Upsher-Smith Laboratories Zembrace SymTouch 3 mg and Tosymra 10 mg. Zembrace SymTouch and Tosymra are both indicated for the treatment of acute migraine with or without aura in adults. Zembrace SymTouch is the only branded sumatriptan autoinjector professionally promoted in the United States and is designed for ease of use and favorable tolerability with a low 3 mg dose. Tosymra is a novel intranasal sumatriptan product formulated with a permeation enhancer that provides rapid and efficient absorption of sumatriptan. Collectively, these products generated product sales of approximately $23 million for the full year 2022.6 Zembrace SymTouch and Tosymra each may provide onset of migraine pain relief in as few as 10 minutes for some patients and currently have patent protection to 2036 and 2031, respectively. Under the terms of the agreement with Upsher-Smith: Tonix Medicines will make an upfront payment of $12 million in cash to Upsher-Smith at closing and an additional $3 million in March 2024, or upon earlier conclusion of the transition services period. In addition, Tonix Medicines will pay approximately $10 million in cash to Upsher-Smith at closing to acquire certain product-related inventories. To support the transition of the products, Upsher-Smith has agreed to provide certain commercial operations, regulatory and other transition services to Tonix Medicines for up to nine months after closing, in exchange for agreed upon service fees. The assets to be acquired include New Drug Applications issued by the U.S. Food & Drug Administration for the products, as well as patents and trademarks related to the products in the United States and in certain countries outside the United States. The closing is expected to take place on June 30, 2023.

07:08 EDT Actinium's Phase 3 SIERRA data awarded Abstract of the Year by SNMMI meeting - Actinium Pharmaceuticals announced that the Society of Nuclear Medicine and Molecular Imaging, SNMMI, 2023 Annual Meeting selected Abstract 685 titled "Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B prior to HCT in relapsed/refractory acute myeloid leukemia: Safety and efficacy results from the pivotal phase 3 SIERRA trial" as the Abstract of the Year. "It is a great honor for this SIERRA data abstract and this team of esteemed abstract authors to have received this award highlighting Iomab-B's potential for people with relapsed and refractory AML," said Sandesh Seth, Chairman and Chief Executive Officer. "Today's SNMMI honor represents the fourth oral presentation of the SIERRA trial data at prestigious medical conferences in 2023, including TCT, EBMT, and EHA. The extensive global recognition of the SIERRA results highlights Iomab-B's potential to transform outcomes for the significant number of people with relapsed or refractory AML by enabling increased access to bone marrow transplant via a targeted radiotherapeutic. We are committed to file our BLA submission with U.S. Food and Drug Administration in the second half of this year in our endeavor to bring this new radiotherapeutic to people with great need."

07:08 EDT Kanzhun announces results of annual general meeting - KANZHUN announced that each of the proposed resolutions submitted for shareholders' approval as set forth in the notice of annual general meeting dated May 24, 2023 has been adopted at the annual general meeting held in Beijing, China. After the adoption of the Proposed Resolutions, all corporate authorizations and actions contemplated thereunder are approved, including, among other things, that each of Mr. Yu Zhang and Mr. Xu Chen is re-elected as an executive director of the Company and Mr. Haiyang Yu is re-elected as a non-executive director of the Company, and the directors of the Company are granted a general unconditional mandate to allot, issue and deal with additional Class A ordinary shares or equivalents and a general unconditional mandate to purchase the Company's own shares, respectively, on the terms and in the periods as set out in the notice of AGM.

07:07 EDT Recurrent Energy secures new EUR150M multi-currency facility with Santander CIB - Canadian Solar (CSIQ) announced that Recurrent Energy has secured a EUR 150M multicurrency facility with Santander Corporate & Investment Banking (SAN). The facility will support Recurrent Energy's growth and strategy to retain greater asset ownership in select markets. Recurrent Energy is one of the world's largest and most geographically diversified utility-scale solar and battery energy storage platforms, with a track record of 9 GW of solar and 3 GWh of battery storage power plants now in operation in 29 countries across five continents. This transaction marks the fourth corporate facility between Recurrent Energy and Santander CIB over the past three years which demonstrates Santander's commitment and continuing support for Recurrent Energy's business. The new facility is composed of a EUR 30 million plus $20 million term loan and a $110.5 million revolving credit facility, with a total duration of three years. This structure provides Recurrent Energy significant flexibility to execute on its growth plans and accelerate its transition to a develop-to-own model in its core markets in North America and Europe, capturing the full value of the projects developed in low-risk markets.

07:06 EDT Mondee joins Russell 2000 Index - Mondee Holdings announced its inclusion as a member of the Russell 2000 Index and the broad-market Russell 3000 Index, as well as the corresponding Russell Growth Indexes. Effective immediately at the opening of today's equity markets, the annual reconstitution is now in effect.

07:06 EDT Invivyd announces alignment with FDA on pathway to potential VYD222 EUA - Invivyd has reached general alignment with the U.S. Food and Drug Administration on a pathway to potential emergency use authorization for VYD222 and anticipated follow-on monoclonal antibody candidates designed to prevent symptomatic COVID-19. The company plans to leverage the pathway, which includes the use of serum neutralizing titers as a correlate of protection in an immunobridging approach to a pivotal clinical trial of VYD222, to rapidly generate data to support a potential VYD222 EUA for the prevention of symptomatic COVID-19. Based on FDA feedback, the use of a correlate of protection in an immunobridging approach to a pivotal EUA-directed clinical trial may be a reasonable approach for a new mAb candidate when clinical trial data from a "prototype" mAb is available, provided that the new mAb candidate: is similar to the prototype mAb such that it leverages a consistent manufacturing platform and has limited structural and functional differences, and has supportive nonclinical data, such as favorable in vitro neutralization data against currently circulating SARS-CoV-2 variants. Invivyd plans to leverage this immunobridging pathway to accelerate the clinical development of VYD222 and anticipated follow-on mAb candidates, with ADG20 or future proprietary mAbs serving as the prototype. The use of adintrevimab as the potential prototype mAb is proprietary to Invivyd and enabled by the robust safety data and clinically meaningful results from a global Phase 2/3 clinical trial of adintrevimab for the prevention of symptomatic COVID-19. VYD222 is a broadly neutralizing, half-life extended mAb candidate in development for the prevention of symptomatic COVID-19 in vulnerable populations, such as immunocompromised people. VYD222 was designed for broad activity and has previously demonstrated in vitro neutralizing activity against prior circulating SARS-CoV-2 variants and current variants of concern, including Omicron sublineages up to and through XBB.1.5. In June 2023, the company announced positive initial safety and serum neutralizing titer data from the ongoing Phase 1 VYD222 clinical trial. Serum neutralizing titers are the same surrogate marker planned for use in the primary endpoint in a pivotal VYD222 clinical trial. Invivyd continues activities to prepare for a VYD222 pivotal clinical trial and is pursuing a rapid initiation of that clinical trial in order to support a potential EUA submission. The company also continues to engage with global regulatory authorities regarding the VYD222 clinical development program.

07:05 EDT IBM enters definitive agreement to purchase Apptio for $4.6B - IBM announced that it has entered into a definitive agreement with Vista Equity Partners to purchase Apptio for $4.6B. The acquisition of Apptio will accelerate the advancement of IBM's IT automation capabilities and enable enterprise leaders to deliver enhanced business value across technology investments. Organizations are digitally transforming their businesses faster than ever, causing IT environments to expand across public and private clouds, with multiple service providers. "Apptio, together with IBM's IT automation software and it's watsonx AI platform, will help businesses around the world manage and optimize enterprise IT spend and derive tangible financial value and operational improvement," the company said. "Technology is changing business at a rate and pace we've never seen before. To capitalize on these changes, it is essential to optimize investments which drive better business value, and Apptio does just that," said Arvind Krishna, CEO and chairman, IBM. "Apptio's offerings combined with IBM's IT automation software and watsonx AI platform, gives clients the most comprehensive approach to optimize and manage all of their technology investments."

07:05 EDT Virgin Galactic announces crew, target date for 'Galactic 01' - Virgin Galactic announced the crew of its first commercial spaceflight, 'Galactic 01,' with a target flight date of June 29. The three-person crew from the Italian Air Force and National Research Council of Italy will board VSS Unity for a 90-minute flight to conduct a series of suborbital science experiments.

07:03 EDT Nordson to acquire ARAG Group for EUR 960M - Nordson announced that it has entered into a definitive agreement to acquire ARAG Group and its subsidiaries in an all-cash transaction that values ARAG at an enterprise value of EUR 960M. Headquartered in Rubiera, Italy, ARAG specializes in the development, production and supply of precision control systems and smart fluid components for agricultural spraying. Its portfolio consists of three key product families: fluid components, such as nozzles, pumps and filters; smart components that measure and control the flow, quantity and location of the dispensed fluid; and control systems that provide a greater variety of input and functionality to the customer. ARAG's broad product portfolio is further supported by differentiated software and data capabilities. Established in 1976, ARAG supports its customers through seven manufacturing and distribution locations globally and a sales network serving more than 80 countries. ARAG is expected to generate EUR 155M in sales in FY23. The transaction reflects a valuation of approximately 16.5 times ARAG's projected 2023 EBITDA. Upon completion of the acquisition, ARAG will operate as a division in Nordson's Industrial Precision Solutions segment.

07:02 EDT TFF Pharmaceuticals awarded $2.97M to develop universal influenza vaccine - TFF Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded the Company a Direct to Phase II Small Business Innovation Research grant of approximately $2.97M to continue development of a novel, pan-flu multivariant mucosal vaccine using the Company's Thin Film Freezing technology. The purpose of the SBIR is to provide funding to support preclinical and IND enabling studies to advance the development of a shelf-stable dry powder formulation of a novel universal influenza virus vaccine, developed in the laboratory of Dr. Ted Ross at the Cleveland Clinic, that is more than 75% effective against symptomatic influenza virus infection and protects against groups I and II influenza A viruses, the form of virus that has historically given rise to all known influenza pandemics and that contributes to seasonal flu each year. If successful, this work could provide a first-in-class stable, easy-to-transport and easy-to-stockpile vaccine that would overcome the vaccine failures that result from mishandling, mismatches between predicted and actual seasonal flu strains, and evolutionary changes in influenza viruses across the season. Successful completion of this Direct to Phase II SBIR grant will fulfill the IND-enabling requirements to potentially advance to human clinical testing.

06:58 EDT Ryder opens new used vehicle sales location in Boston South - Ryder System announced the opening of a new used vehicle sales center located in Norwood, Massachusetts. Located between Boston and Providence, Ryder's Norwood operation is intended to absorb growing industry demand with a 1,100 square foot facility.

06:56 EDT Castellum reports 10M shares of common stock traded on June 23 - Castellum also notes that over 10 million shares of its common stock traded on Friday, June 23, 2023. "We are pleased that our cost reduction and growth story appears to have resonated with our existing and some new stockholders and has translated into greater interest in our stock," said CEO Mark Fuller. "Friday's activity represents record trading volume for Castellum and helps provide our stockholders with greater liquidity for their holdings. With about 14 million shares in our public float, Friday's trading represented over 70% of our public float. We will continue to spend time over the coming weeks and months meeting with current and prospective shareholders to tell the Castellum story and encourage people to join us as larger shareholders of the Company."

06:55 EDT Pharvaris announces FDA removal of clinical hold on deucrictibant - Pharvaris announced the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for deucrictibant for the on-demand treatment of HAE following review of data from a preplanned interim analysis of the ongoing 26-week nonclinical study. Pharvaris expects to submit data from the 26-week nonclinical study by the end of 2023 to address the remaining hold on the IND application for deucrictibant for prophylactic treatment of HAE.

06:53 EDT Genesco board increases share repurchase authorization by $50M - Genesco announced that its board of directors has authorized a $50M increase to its existing $200M share repurchase authorization. Under Genesco's existing $200M share repurchase, since September 2019 the Company has repurchased 3.9M shares at a total cost of approximately $189.5M leaving the remaining authorization of $10.5M under the existing program. This includes repurchasing during the current quarter approximately 676,000 shares for a total cost of $14.5M, at an average price of $21.41 per share. Since December 2018, the Company has repurchased an aggregate of approximately 9.2 million shares at a total cost of approximately $415M. These shares represent more than 46% of the shares outstanding at the start of these purchases.

06:48 EDT OneSpaWorld to be exclusive spa provider for Crystal Cruises - OneSpaWorld Holdings has announced entry into a new agreement with Crystal Cruises for a five-year term commencing in June 2023. OneSpaWorld will be the exclusive provider of spa, salon, medi-spa and fitness services onboard Crystal's newly refurbished Crystal Serenity and Crystal Symphony, as well as any additional vessels coming into service during the term.

06:46 EDT J.Jill added to Russell 3000 Index - J.Jill announced that is has been added to the broad-market Russell 3000 Index, effective after U.S. markets open, June 26, 2023, as part of the 2023 Russell indexes annual reconstitution.

06:39 EDT Trane participates in three projects advancing heat pump technologies - Trane Technologies announced its participation in three projects accelerating next-generation heat pump efficiency to reduce energy and emissions across multiple industrial sectors. These projects were recently awarded U.S. Department of Energy grants for the research and development of transformational technologies aimed at decarbonizing heavy industry. Lead research partners and project descriptions: DOE's Oak Ridge National Laboratory - Develop and test an ultra-high temperature industrial heat pump, with multiple systems-level design considerations including advanced, AI-enabled integration and process control, low-global warming potential refrigerants and waste heat recovery. Purdue University - Develop a higher-temperature industrial heat pump that leverages 3D printing for the system's compressor and considers design factors such as thermal energy storage for optimized integration of industrial processes. Texas A&M University's Engineering Experiment Station - Develop a high-performance heat pump system that integrates dehumidification, low-cost sensors and predictive controls to improve methods for drying foods while ensuring food quality and lowering energy costs.

06:35 EDT New Found Gold provides update on 3D seismic survey at Queensway Project - New Found Gold provides an update on its 3-D seismic survey that will cover 47 km2 along the Appleton and JBP Fault Zones at its Queensway Project. New Found's 100%-owned Queensway Project comprises a 1,662km2 area, accessible via the Trans-Canada Highway, 15km west of Gander, Newfoundland and Labrador. Highlights: The seismic program was announced on March 7, 2023, and is being conducted by HiSeis, an industry leader in hard rock seismic surveys. Preparation and line construction for the seismic program was completed on June 25, 2023. The Company is pleased to announce it has now entered the acquisition phase of the program. The acquisition phase utilizes over 20,000 energy source points generating 3-D seismic data across a 47km2 grid area and is expected to wrap up by early August. At such time, the program will enter its final phase: data compilation and interpretation. This final phase is targeted to be complete by late September with more detailed interpretation and analysis expected to continue. Greg Matheson, COO, stated: "3-D seismic could change the game at Queensway as we look to deeper layers of the gold system, as well as areas more distal from the Appleton Fault corridor. Our exploration team has gained a deep understanding of the mineralized system at Queensway through extensive exploration efforts and roughly 425,000m drilled to date. This includes recognition of high-grade gold mineralization found further from the AFZ, including recent discoveries at Jackpot and Iceberg East. We have an excellent training set of 16 near-surface zones that will aid in fingerprinting new potential host structures for gold mineralization. By early October, we will be in a position to drill test targets highlighted by the 3-D seismic. This program represents a significant investment into the project that upholds our long-term view of Queensway and it is our belief that it will provide benefits for both exploration and development for years to come. I would like to thank HiSeis and the many seismic contractors working on the ground who have carried out a very ambitious project with high regard for safety and efficiency."

06:32 EDT Denison Mines reports increase in economic results for Wheeler River - Denison Mines reported the results of the Feasibility Study completed for In-Situ Recovery, or ISR, mining of the high-grade Phoenix uranium deposit and (a cost update to the 2018 Pre-Feasibility Study for conventional underground mining of the basement-hosted Gryphon uranium deposit. With the successful completion of the Phoenix FS, Denison has advanced the planned Phoenix ISR project through the technical de-risking process and has already commenced the first phases of project execution. Phoenix and Gryphon are part of the Wheeler River Uranium Project, which is the largest undeveloped uranium mining project in the infrastructure-rich eastern portion of the Athabasca Basin region in northern Saskatchewan, Canada. Denison has an effective 95% ownership interest in Wheeler River and is the project operator.

06:28 EDT AstraZeneca's Soliris recommended for EU approval by CHMP for children with gMG - Soliris has been recommended for marketing authorization in the European Union for expanded use to include the treatment of refractory generalized myasthenia gravis, or gMG, in children and adolescents aged six to 17 years who are anti-acetylcholine receptor antibody-positive, AstraZeneca announced.

06:08 EDT Coherent, TriEye demonstrate laser-illuminated SWIR imaging system - Coherent and TriEye announced their joint demonstration of a laser-illuminated SWIR imaging system for automotive and robotic applications. The companies said, "The growing number of use cases for SWIR imaging, which expands vision in automotive and robotics beyond the visible spectrum, is driving demand for low-cost mass-market SWIR cameras. The companies leveraged TriEye's spectrum enhanced detection and ranging product platform and Coherent's SWIR semiconductor laser to jointly design a laser-illuminated SWIR imaging system, the first of its kind that is able to reach lower cost points while achieving very high performance over a wide range of environmental conditions. The combination of these attributes is expected to enable wide deployment in applications such as front and rear cameras in cars as well as vision systems in industrial and autonomous robots."

06:04 EDT Reviva Pharmaceuticals to be added to Russell Microcap Index - Reviva Pharmaceuticals announced that the Company will be added to the Russell Microcap Index, effective after the United States market opens on Monday, June 26, 2023, following the conclusion of the 2023 Russell indexes annual reconstitution.

06:01 EDT Rockwell Medical added to Russell Microcap Index - Rockwell Medical announced that the Company was added to the Russell Microcap Index. The newly reconstituted index took effect after the market close on Friday, June 23, 2023.

05:49 EDT Aston Martin announces strategic supply agreement with Lucid Group - Aston Martin (ARGGY) announced the formation of a new supply agreement with electric vehicle technologies company, Lucid Group (LCID). The proposed agreement announced this morning to the London Stock Exchange would see Lucid supply Aston Martin with electric vehicle technologies, the company said in a statement. Access to Lucid's current and future powertrain and battery technology will be at the center of Aston Martin's all-new in-house Battery Electric Vehicle platform. Lawrence Stroll, Executive Chairman of Aston Martin, said: "The supply agreement with Lucid is a game changer for the future EV-led growth of Aston Martin. Based on our strategy and requirements, we selected Lucid, gaining access to the industry's highest performance and most innovative technologies for our future BEV products... Along with Mercedes-Benz (MBGYY), we now have two world-class suppliers to support the internal development and investments we are making to deliver our electrification strategy. With the recently announced long-term partnership with Geely (GELYF), we will also gain the opportunity to access their range of technologies and components, as well as their deep expertise of the key strategic market of China." Reference Link

05:12 EDT Innate Pharma announces first patient dosed in MATISSE trial - Innate Pharma (IPHA) announced the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study, sponsored by Innate Pharma, evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab and chemotherapy, in treatment-naive patients with resectable early stage non-small cell lung cancer. Innate is responsible for conducting the study and shares study costs with AstraZeneca (AZN). AstraZeneca supplies clinical trial drugs.

05:06 EDT Lilium receives FAA G-1 Certification Basis - Lilium announced that it has received the Federal Aviation Administration, or FAA, G-1 Certification Basis necessary for type certificate validation of its Lilium Jet by the FAA. In 2020, Lilium's primary airworthiness authority, the European Union Aviation Safety Agency, or EASA, issued its certification basis for the Lilium Jet. To enable global operations, Lilium is pursuing concurrent certification of the Lilium Jet through validation by the FAA under the provisions of the Bilateral Aviation Safety Agreement between the EU and U.S. Lilium is one of a few eVTOL companies seeking dual certification in the EU and the U.S. and the only pioneer holding both an EASA and FAA certification basis for a powered lift eVTOL aircraft.